BioGenCell has received the approval of both the Israeli Ministry of Health (MOH) and the Belgium Ministry of Health (FAMHP-Federal Agency for Medicines and Health Products) to continue its clinical trials on a larger scale as a double-blind placebo-controlled study.

Share this Article
Share on facebook
Share on linkedin
Share on email